Trial Profile
Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant interleukin 21 (rIL-21) administered in combination with Rituxan (rituximab) in subjects with B-cell non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Denenicokin (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors ZymoGenetics
- 31 Oct 2007 Status changed from recruiting to in progress.
- 11 Jul 2006 New trial record.